Engineered JAZF1 peptide variants boost TR4 binding >2,200-fold, suppressing POMC expression in Cushing's disease cells
Background
The testicular orphan receptor 4 (TR4) plays a crucial role in Cushing's disease (CD) pathogenesis by regulating pro-opiomelanocortin (Pomc) expression, which leads to excessive adrenocorticotropic hormone (ACTH) secretion. While the endogenous repressor juxtaposed with another zinc finger gene 1 (JAZF1) naturally inhibits TR4 activity, its low binding affinity (KD = 2,246nM) limits its therapeutic utility. There's a critical need for high-affinity TR4 modulators to effectively control the TR4-Pomc axis and mitigate ACTH hypersecretion in CD.
Study Design
Researchers employed an iterative structure-based lead optimization strategy to enhance the JAZF1 peptide scaffold. This involved virtual screening using Discovery Studio for in silico saturation mutagenesis, progressing from single-point to multi-site combinatorial substitutions. These computationally designed variants were then validated through incremental experimental binding assays. The optimized peptides were subsequently tested in AtT-20 tumor cells to assess their impact on Pomc expression and cell proliferation. High-affinity small molecule nilotinib (KD = 4.83nM) served as a positive control for comparison.
Results
The recursive optimization process successfully identified two triple-mutant JAZF1 peptides, V56L/A68Y/A69R and D67L/A68Y/A69R, which demonstrated significantly enhanced binding affinity for TR4. These engineered peptides achieved more than a 2,200-fold improvement in TR4 binding affinity compared to the endogenous JAZF1 (KD = 2,246nM).
Key Findings
- Endogenous JAZF1 exhibits low TR4 binding affinity (KD = 2,246nM), limiting its therapeutic potential.
- Iterative structure-based design yielded two triple-mutant JAZF1 peptides (V56L/A68Y/A69R and D67L/A68Y/A69R).
- These engineered JAZF1 peptides achieved >2,200-fold enhancement in TR4 binding affinity.
- The high-affinity JAZF1 variants effectively downregulated
Pomcexpression inAtT-20tumor cells. - Engineered JAZF1 peptides inhibited proliferation of
AtT-20tumor cells.
Why It Matters
This study provides a compelling proof-of-concept for targeting the JAZF1-TR4-Pomc axis with high-affinity peptides as a novel therapeutic strategy for Cushing's disease. By designing JAZF1 variants that potently bind TR4, it's possible to effectively downregulate Pomc expression and inhibit tumor cell proliferation, offering a new avenue to modulate ACTH hypersecretion. While currently an in vitro finding, this rational design approach could pave the way for developing advanced peptide-based drugs. Future research will need to translate these findings into in vivo models to establish pharmacokinetics and efficacy, moving closer to a usable clinical protocol for CD patients.
jazf1
tr4
pomc
cushing's disease
peptide design
in vitro